key: cord-1016759-194eaad8
authors: Candoni, Anna; Pizzano, Umberto; Fabris, Martina; Curcio, Francesco; Fanin, Renato
title: Seroconversion and kinetic of anti SARS‐COV‐2 antibodies in 25 patients with hematological malignancies who recovered from SARS‐COV‐2 infection
date: 2021-05-05
journal: Hematol Oncol
DOI: 10.1002/hon.2872
sha: 9fd99edb302114d1b98e0269b89efa59c53344f5
doc_id: 1016759
cord_uid: 194eaad8

nan

with increased IgM and IgG titers observed during the first month.

IgM levels, after peaking by day 30, gradually decreased and were undetectable by day 180. The long-lasting persistence of IgG has not been clearly demonstrated. [1] [2] [3] [4] [5] We evaluated the humoral response and kinetics of IgM and IgG against SARS-CoV-2 in 25 hematologic patients, receiving anticancer therapy, who were followed after real-time quantitative polymerase chain reaction (RT-qPCR) confirmation of SARS-CoV-2 infection. The The IgM and IgG antibodies against SARS-CoV-2 spike protein (subunity S1 and S2) were tested by chemiluminescence immunoassay (CLIA) with a positive cut-off value of 12 UA/ml for both IgG and IgM. The specificity and sensibility of this assay was 98,5% and 97,4%, respectively. 6 All patients signed written informed consent for the serological test. To assess the kinetics of antibody titers, in our convalescent COVID-19 patients, serum IgM and IgG levels were In summary, although we analyzed a limited number of cases, patients with hematological malignancy appear to have an antibody response to SARS-CoV-2 and a high rate of seroconversion (84%).

However, the kinetic of antibody levels may suggest that the duration of antibody-mediated protection against re-infection with SARS-CoV-2 may be short-lasting. 7, 8 If confirmed in a larger number of cases, these findings would suggest that stringent infection prevention and control measures must be maintained in hematological patients who have recovered from COVID-19. In addition, our results would suggest that hematological patients could require a periodic re-vaccination. Obviously, additional studies of both humoral and cellular immunity (T and memory B cells) will be necessary to better understand the dynamics, duration, and intensity of the overall immunological response to SARS-CoV-2 infection in hematological malignancy patients.

The authors declare no conflicts of interest.

Anna Candoni performed the research, collected the data and wrote the letter. Umberto Pizzano collected the data, Martina Fabris 

Antibody responses to SARS-CoV-2 in patients with COVID-19

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection

Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients

Re-infection by COVID-19: a real threat for the future management of pandemia? Infectious Diseases

Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19